U.S. Renewable Energy Stock News

Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease access for an expanding network of authorized treatment centers. This move deepens Cencora’s presence in complex cell and gene therapies, highlighting its role in handling highly specialized, patient-specific treatments that can be operationally challenging for providers. Next, we’ll examine...

On 8 June 2026, S&P Global announced a collaboration with Cohere to integrate its financial data into Cohere’s North enterprise AI platform, enabling secure, citation-backed research and analysis for customers combining S&P’s datasets with their own. This move highlights S&P Global’s push to make its intelligence LLM-ready and embedded in third-party AI workflows, potentially reshaping how professionals access and use its data. We’ll now examine how embedding S&P Global’s data inside...

GSK’s US$10.6b move to buy Nuvalent has pushed oncology back into the spotlight, reminding investors how a single deal can reshape expectations across cancer drug developers and related healthcare stocks. When a large buyer pays up for late stage lung cancer assets, it can reset how the market thinks about pipelines, partnerships and future deal potential across the sector. This article looks at 3 stocks from our Healthcare Oncology Pharmaceuticals screener that are exposed to this news, and...

In early June 2026, NewAmsterdam Pharma filed a US$37.57 million shelf registration for 1,150,000 ordinary shares tied to its ESOP, while shareholders also approved Deloitte Accountants B.V. as external auditor for the 2026 fiscal year and statutory Dutch reporting. Investor attention has been amplified after prominent investor Stanley Druckenmiller highlighted NewAmsterdam Pharma as a top non‑AI idea, coinciding with high-profile healthcare conference appearances to discuss its late-stage...

Recent performance snapshot and context SL Green Realty (SLG) has been drawing attention after a recent stretch of mixed returns, with the stock up over the past week and past 3 months but down over the past year. See our latest analysis for SL Green Realty. For context, the stock’s recent upswing, including a 27.02% 90 day share price return, contrasts with a 20.35% decline in 1 year total shareholder return. As a result, near term momentum appears to be rebuilding from a weaker longer term...

ASCO data puts NeXT Personal in focus Personalis (PSNL) is back in the spotlight after releasing new clinical data at the 2026 ASCO Annual Meeting on its NeXT Personal platform for ultrasensitive minimal residual disease detection across six solid tumor types. For you as an investor, the key takeaway is that ASCO collaborators reported early relapse detection ahead of imaging, sensitivity at very low ctDNA levels, and links between molecular clearance and future recurrence or progression...

Glacier Bancorp (GBCI) stock has drawn fresh attention after recent trading left it around $47.12, with mixed short term returns that include gains over the past 3 months but a decline over the past month. See our latest analysis for Glacier Bancorp. At around $47.12, the stock’s recent 3 month share price return of 5.39% contrasts with a 3.42% move down over the past month, while the 1 year total shareholder return of 12.90% sits alongside a modest total shareholder loss over 5 years. This...

Iridium Communications (IRDM) drew fresh attention after Oppenheimer shifted its view to Outperform and raised its expectations for the stock, a supportive signal that arrived despite ongoing questions around valuation and insider share sales. See our latest analysis for Iridium Communications. That upgrade landed against a backdrop of strong recent momentum, with a 30 day share price return of 14.51% and a 90 day share price return of 91.20%. The 1 year total shareholder return of 70.84%...

Victoria's Secret & Co. ( NYSE:VSXY ) just released its latest quarterly results and things are looking bullish. It was...

In early June 2026, Planet Labs PBC reported first-quarter revenue of US$94.15 million versus US$66.27 million a year earlier, alongside a net loss of US$138.87 million and filed a new shelf registration for an at-the-market follow-on equity offering of up to US$1.50 billion in Class A common stock. At the same time, Planet advanced its Pelican satellite roadmap with the Pelican-11 tech demonstrator and issued stronger revenue guidance, highlighting a business balancing heavy investment,...

In early June 2026, Allient reported Q1 revenue growing 4.6% year on year in line with expectations, even as EBITDA and EPS came in below analyst estimates. Management’s emphasis on strong booking growth and alignment with long-term electrification and automation trends has coincided with rising hedge fund interest, even as some investors trim positions amid earnings sustainability concerns. We’ll now examine how Allient’s recent booking strength and focus on electrification and automation...

Recent performance and what has caught investors’ attention Reinsurance Group of America (RGA) has drawn fresh interest after recent share price moves, with the stock ending the latest session at US$201.21 and sitting slightly down year to date. Short term returns have been mixed, with the stock down about 2% over the past week, down roughly 4% over the past month, and lower by around 3% over the past 3 months, while the 1 year total return is slightly positive. See our latest analysis for...

Zevra Therapeutics recently disclosed that shareholders at its June 4, 2026 annual meeting rejected an amendment to phase out the company’s classified board structure, which would have shifted all directors to one-year terms beginning with the 2027 annual meeting. Around the same time, Zevra moved to strengthen its intellectual property position by asking the U.S. Food and Drug Administration to list a new MIPLYFFA patent in the Orange Book, aiming to extend patent protection to 2041 and...

Fluence Energy (FLNC) has been in focus after its collaboration with Siemens and Nvidia to design AI data centers that use Fluence battery storage. This move ties the stock to growing AI power demand. See our latest analysis for Fluence Energy. After a sharp run that has lifted the 1 year total shareholder return to a very large gain of about 7x, recent trading has been choppy. The 90 day share price return is 42.6%, while the 7 day share price return is a weaker 11.3% and the 30 day share...

Recent performance snapshot With no single headline event driving Eastman Chemical (EMN) today, investors are focusing on how the stock has moved recently and how that lines up with the company’s latest financial profile. See our latest analysis for Eastman Chemical. At a share price of US$71.67, Eastman Chemical has given investors a year to date share price return of 11.39%, while the 1 year total shareholder return is down 5.95%. This suggests that recent momentum has improved compared...

In late May 2026, Cheniere Energy signed a US$4.69 billion engineering, procurement and construction contract with Bechtel to build Train 7 and supporting infrastructure for the first phase of its Sabine Pass LNG expansion in Louisiana, while also issuing long‑dated senior notes to help fund the project. This move to expand liquefaction capacity comes as Middle East disruptions and a sharper focus on energy security increase the importance of reliable U.S. LNG supply, reinforcing Cheniere’s...

In recent days, McKesson reported a mixed quarter but reinforced its long‑term plans, while major Wall Street banks reaffirmed positive views on the company’s outlook and multi-year guidance. At the same time, ongoing insider share sales and assessments of the stock as modestly overvalued have sharpened investor focus on how credible its fiscal 2027 ambitions really are. We’ll now examine how analysts’ support for McKesson’s fiscal 2027 guidance could influence the company’s existing...

Crinetics Pharmaceuticals (CRNX) has drawn investor attention after recent trading, with the stock closing at US$33.48 and showing mixed short term performance, including a decline of around 11% over the past month. See our latest analysis for Crinetics Pharmaceuticals. Recent price weakness, including a 30 day share price return of around 11% down and a year to date share price return of around 28% down, contrasts with a 1 year total shareholder return of 3.7% and a 3 year total shareholder...

What sparked fresh interest in Kodiak Gas Services? Recent attention on Kodiak Gas Services (KGS) was kicked off by new analyst coverage from Jefferies, along with the company’s plan to sell over 10 million shares through an underwritten public offering priced at US$71. See our latest analysis for Kodiak Gas Services. Those announcements have come during a strong run, with the share price at US$67.63 after a 3.87% 1 day share price return and 79.68% year to date share price return. The 1 year...

Helmerich & Payne’s board on June 3, 2026, declared a quarterly cash dividend of US$0.25 per common share, payable on September 1 to shareholders of record as of August 18, alongside reporting a fiscal second-quarter net loss influenced by a non-cash impairment. The company also exceeded its asset divestiture goal with the sale of the Utica Square retail center and renewed a major Caspian Sea offshore operations and maintenance contract through its TURAN joint venture, reinforcing its focus...

The SpaceX IPO hype is not just about one company; it is reshaping attention and capital around space and AI, and that can create both openings and pressure points for other stocks. With a US$75 billion offer for 5% of the company and a US$1.75 trillion valuation tied closely to its xAI ambitions, investors are suddenly rethinking which companies might lose out as money and headlines gravitate toward this new listing. This article highlights 3 stocks exposed to that news, each at risk of...

Stock performance snapshot Varonis Systems (VRNS) has seen mixed share performance recently, with a gain of around 1% over the past day and a decline of about 8% over the past week. Over the past month the stock is up roughly 16%, while the past 3 months show a gain of about 38%. Over the past year, however, the stock is down around 35%. See our latest analysis for Varonis Systems. At a share price of $33.04, Varonis Systems has recently shown firm short term share price momentum, with a 30...

Werner Enterprises recently reported that sales have fallen for two consecutive years and earnings per share have dropped sharply, underscoring difficult end-market conditions and pressure on profitability. Management’s recent capital investments are currently destroying value rather than enhancing returns, raising questions about how effectively Werner is deploying resources in a challenging freight market. We’ll now examine how Werner’s recent earnings decline and value-destructive...

Vertex Pharmaceuticals (NasdaqGS:VRTX) reported new clinical data for its next-generation cystic fibrosis therapy ALYFTREK in young children. The company also outlined progress on global regulatory submissions for ALYFTREK and TRIKAFTA in pediatric populations. The updates focus on expanding treatment access to children as young as 2 years old and on long term safety findings in older patients. Vertex Pharmaceuticals sits at the center of the cystic fibrosis treatment market, and the latest...